<div class="entities" style="line-height: 2.5; direction: ltr">Admission Date:  [**2183-8-31**]              Discharge Date:   [**2183-9-15**]<br><br>Date of Birth:  [**2121-8-27**]             Sex:   F<br><br>Service: MEDICINE<br><br>Allergies:<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Penicillins
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
<br><br>Attending:[**First Name3 (LF) 2042**]<br>Chief Complaint:<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Pancreatitis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br><br>Major Surgical or Invasive Procedure:<br>None<br><br><br>History of Present Illness:<br>62 yo female with history of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hypothyroidism
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 and chronic back<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 s/p multiple back surgeries wuth 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    epidural
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    steroid
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    injection
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
<br>2 months prior to admission who presented to OSH with 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    fever
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 for<br>5 days, found to have 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pancreatitis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 and 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    multifocal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pneumonia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
,<br>transferred to [**Hospital1 18**] for ERCP.<br>On admission at OSH [**8-28**], she was found to have elevated lipase<br>(peak 1690, down to 613 on transfer), elevated LFTs (admission<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    AST
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 130/ALT 143/Alk phos 179, transfer AST 43/ALT 67/Alk phos<br>113/T bili 0.5), and MRI findings consistent with acute<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pancreatitis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
. MRCP showed no fluid collection, pseudocyst,<br>abscess, biliary duct dilation, nor pancreatic duct dilation.<br>Patient was initially managed with 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    IVF
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
. She became increasingly<br>short of breath on [**8-29**] however, saturating 90% on 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    4L
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    O2
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, and<br>was transferred to the OSH ICU. CXR showed bilateral patchy<br>infiltates concerning for 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    biliary
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    sepsis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
. CT Chest showed<br>extensive consolidation with air bronchograms in RUL and ground<br>glass opacities in LUL as well as small bilateral pleural<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    effusions
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
. CT pelvis negative for 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    abscess
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
. She was started on<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    antibiotics
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 (
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    vanc
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    zosyn
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    moxifloxacin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
) and cultures were sent<br>(pending). She is being transferred to [**Hospital1 **] for ERCP on Tuesday.<br>.<br>In the [**Hospital Unit Name 153**], she is afebrile and pain-free.<br>Review of systems:<br>(+) Per HPI<br>(-) Denies fever, chills, night sweats, recent weight loss or<br>gain. Denies headache, sinus tenderness, rhinorrhea or<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    congestion
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
. Denies 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    cough
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
, 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    shortness
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    of
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    breath
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
, or 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    wheezing
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.<br>Denies 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    chest
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
, chest 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pressure
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
, palpitations, or weakness.<br>Denies nausea, vomiting, diarrhea, constipation, abdominal pain,<br>or changes in bowel habits. Denies dysuria, frequency, or<br>urgency. Denies arthralgias or myalgias. Denies rashes or skin<br>changes.<br><br><br>Past Medical History:<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Hypothyroidism
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Chronic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    back
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 s/p multiple surgeries and 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    epidural
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    steroid
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
<br>shots<br><br><br>Social History:<br>From [**Location (un) 6185**], came to [**Location (un) 86**] to visit children.<br>- Tobacco: none<br>- 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Alcohol
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
: none<br>- Illicits: none<br><br><br>Family History:<br>Negative for malignancy, daughter has 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    polymyositis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br><br>Physical Exam:<br>General: Alert, oriented, no acute distress, afebrile<br>HEENT: Sclera anicteric, oropharynx clear<br>Neck: supple,<br>Lungs: diffuse bilateral rhonchi posteriorly throughout lung<br>fields as well as anteriorly<br>CV: Regular rate and rhythm, normal S1 + S2, no murmurs, rubs,<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    gallops
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>Abdomen: soft, non-tender, non-distended, bowel sounds present,<br>no rebound tenderness or guarding, no organomegaly<br>GU: +foley<br>Ext: warm, well perfused, 2+ pulses, 1+ non pitting 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    edema
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br><br><br>Pertinent Results:<br>OSH Labs:<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lipase
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
: peak 1690, down to 613 on transfer<br>LFTs: admission AST 130/ALT 143/Alk phos 179, transfer AST<br>43/ALT 67/Alk phos 113/T bili 0.5  LDH: 244  lactate: 1.3<br>WBC: 12.8<br>TG: 241<br>TSH 0.38  free T 4 1.8<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Blood
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 cx pending<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    UA
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    negative
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br><br>MRI/MRCP: Findings suggest mild evolving acute 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pancreatitis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
,<br>without organizing or drainable fluid collection, pseudocyst or<br>abscess. No evidence for pancreatic hemorrhage or necrosis.<br>Small right and tiny left 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pleural
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    effusions
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 are documented.<br><br>Admission Labs:[**2183-9-1**] 04:44AM WBC-8.5 RBC-3.35* Hgb-9.5*<br>Hct-28.8* MCV-86 Plt Ct-268<br>[**2183-8-31**] 09:06PM Glucose-103* UreaN-5* Cr-0.8 Na-143 K-4.3<br>Cl-109* HCO3-22<br>[**2183-8-31**] 09:06PM ALT-48* 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    AST
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    -
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
48* AlkPhos-99 TotBili-0.5<br>[**2183-9-1**] 04:44AM 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    proBNP
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-[**Numeric Identifier 88471**]*<br>[**2183-8-31**] 09:06PM 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Albumin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-2.9* 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Calcium
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-8.3* 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Phos
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-2.0* Mg-2.1<br><br>[**2183-9-4**] Chest CT:CT CHEST<br>REASON FOR EXAM: Characterize diffuse opacities described in<br>prior chest<br>x-ray from [**8-31**] and [**9-1**].<br><br>TECHNIQUE: Multidetector CT through the chest was acquired<br>without 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    IV
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    contrast
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
. 5-
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ,
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Dosage</span>
</mark>
 1.25-mm collimation images, sagittal and coronal<br>reformations were provided and reviewed.<br><br>FINDINGS: The airways are patent to the segmental level. There<br>is increase in number and size of mediastinal lymph nodes<br>located in all stations. They measure up to 8 mm in the<br>prevascular station, 10 mm in the upper pretracheal station, in<br>the left lower paratracheal station measuring 10 mm, precarinal<br>station up to 12 mm. Evaluation of hilar lymph nodes is limited<br>due to the lack of 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    IV
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    contrast
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
. Some of the lymph nodes are<br>calcified in the left hilum and the left paraesophageal station.<br>There is mild cardiomegaly. There is no pericardial effusion.<br>Mild-to-moderate calcifications are in the LAD and circumflex<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    coronary
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    arteries
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
. Cardiac size is normal.<br><br>Large right and moderate left 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pleural
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    effusions
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 are layering and<br><br>nonhemorrhagic, associated with adjacent areas of atelectasis. A<br>noncalcified lung nodule in the right lower lobe measures 5 mm<br>(4, 105). Large multiple areas of ground glass opacity<br>associated with smooth interlobular septal 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    thickening
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 are<br>present in the upper lobes bilaterally, right greater than left.<br>The upper abdomen is unremarkable. There are no bone findings of<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    malignancy
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br><br>IMPRESSION: Improved 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pulmonary
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    edema
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
. Bilateral pleural<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    effusions
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.<br>5-mm right 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lower
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lobe
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lung
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 nodule. Followup in one year is<br>recommended.<br>Cardiomegaly.<br><br><br>Brief Hospital Course:<br>1) 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Acute
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-ADE</span>
</mark>
 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    renal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-ADE</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    failure
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
: Developed after transfer from OSH,<br>likely 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ATN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-ADE</span>
</mark>
 secondary to 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    contrast
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 load on [**2183-8-30**] + SIRS +<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hypotension
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 in the ICU overnight the evening of [**2183-8-31**]. FENa<br>5%, lytes remained stable. Patient was given continuous 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    IV
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    fluids
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 and developed 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    post
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-ADE</span>
</mark>

<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    -
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-ADE</span>
</mark>

<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ATN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-ADE</span>
</mark>
 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    diuresis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-ADE</span>
</mark>
 complicated by one<br>episode of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hypernatremia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
. Her creatinine slowly improved and was<br>1.5 at the time of discharge.<br>.<br>2) ?
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Multifocal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pneumonia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
: Could very well have represented ARDS,<br>but given fevers, persistent 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 requirement and concerning<br>CT at OSH patient was treated with 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Vanc
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    /
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Zosyn
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
. Blood cultures<br>were sent at the OSH and remained negative. Patient was weaned<br>off of 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 and remained stable on room air.<br>.<br>3) 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Pancreatitis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
: 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Lipase
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 significantly decreased by the time of<br>transfer; patient was never nauseous or with abdominal pain.<br>ERCP was not felt to be indicated and she was followed<br>clinically as her diet was advanced. A repeat MRCP performed on<br>[**2183-9-11**] was normal.<br>.<br>4) 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Intermittent
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    fevers
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
: Patient had continued low-grade fevers<br>throughout her hospital stay. CXR, UA, blood cultures, and MRCP<br>were unrevealing. Infectious disease was consulted and<br>suggested that a drug reaction to 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    penicillin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 be considered as<br>part of the differential diagnosis, but also recommended Hep C,<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Hep
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    B
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
, 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    RPR
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
, and 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    HIV
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 as initial work up. These were obtained and<br>returned negative prior to the patient's discharge except for<br>the 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Hepatitis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    C
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 serologies which are still pending. As the<br>workup was in progress, the patient's fever curve decreased and<br>she subsequently became afebrile 3 days prior to her discharge.<br>Because the patient deffervesced, the infectious disease service<br>did not feel that an echocardiogram, blood smears for 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    parasites
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
,<br>or other serologies needed to be pursued as an inpatient. The<br>service made two other recommendations:<br>A) a shorter follow up interval for her small lung nodule than<br>12 months due to her history of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    fever
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.<br>B) That after her acute illness subsided to consider checking<br>crp, esr and nuclear medicine studies if all else was negative;<br>and to also consider checking anaplasma/ehrlichia serologies,<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    anca
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, [**Doctor First Name **], spep/upep and consider Rheumatological evaluation +/-<br>Oncology evaluation.<br>.<br>5) 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Maculo
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-ADE</span>
</mark>
 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    papular
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-ADE</span>
</mark>
 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    rash
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-ADE</span>
</mark>
: The patient developed a 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    rash
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-ADE</span>
</mark>
 across her<br>abdomen, back and all 4 extremities 4 days prior to her<br>discharge. The 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    rash
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-ADE</span>
</mark>
 was thought to be part of a possible drug<br>reaction to 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    penicillins
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 although the timing was after she had<br>discontinued her 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    zosyn
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
. It was treated with 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    benedryl
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 and 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    sarna
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
<br>and almost completely resolved by the time of discharge.<br>.<br>6) Increased mediastinal lymphadenpathy and 5mm lung nodule on<br>CT as noted above -  requires follow-up in [**4-30**] months.<br><br><br>Medications on Admission:<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    prilosec
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    20
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    synthroid
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    75
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mcg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lipitor
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
<br><br>Discharge Medications:<br>
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    1
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Strength</span>
</mark>
. 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    levothyroxine
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    75
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mcg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Tablet
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
 Sig: 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    One
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    (
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Dosage</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    1
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Dosage</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    )
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Tablet
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    PO
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    DAILY
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>(
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
).<br><br><br>Discharge Disposition:<br>Home<br><br>Discharge Diagnosis:<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Pancreatitis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Acute
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Renal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Failure
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Pneumonia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br><br><br>Discharge Condition:<br>Mental Status: Clear and coherent.<br>Level of Consciousness: Alert and interactive.<br>Activity Status: Ambulatory - Independent.<br><br><br>Discharge Instructions:<br>You were transferred here from an outside hospital for<br>evaluation of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pancreatitis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 and 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pneumonia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
. Your 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pancreatitis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>improved without further intervention. Your 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pneumonia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 was<br>treated with broad spectrum 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    antibiotics
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
. Your hospital course<br>was complicated by 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    acute
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    renal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    failure
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
, which improved with 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    IV
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    fluids
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
. You had low-grade fevers until the end of your hospital<br>stay without a clear cause. You were  seen in consultation by<br>our Infectious Disease specialists who recommended several 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    blood
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
<br>tests for look for a possible infection that may be causing your<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    fevers
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
. All of these tests were negative, including Hepatitis 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    B
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
,<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    HIV
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
, and an RPR test. You have a pending test for Hepatitis C<br>that you can check at your follow up appointment. The infectious<br>disease doctors recommended that [**Name5 (PTitle) **] get an echocardiogram of<br>your heart, but your fevers have gone away before this test<br>could be scheduled in the hospital. You should follow up with<br>your primary physician to consider whether an echocardiogram<br>should be done as an outpatient. A small lung nodule was seen on<br>your CT scan of your lungs that will need to be followed up with<br>your primary physician.<br><br>There have been no changes to your home medications.<br><br>Followup Instructions:<br>Please follow-up with your primary care doctor within one week<br>of discharge.<br><br>Department: [**Hospital3 249**]<br>When: FRIDAY [**2183-9-19**] at 9:30 AM<br>With: [**Company 191**] POST [**Hospital 894**] CLINIC [**Telephone/Fax (1) 250**]<br>Building: SC [**Hospital Ward Name 23**] Clinical Ctr [**Location (un) 895**]<br>Campus: EAST     Best Parking: [**Hospital Ward Name 23**] Garage<br><br><br><br></div>